The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Marks Peter Ashley | Director | Buy(P) | 48K | $0.50 | $24K |
| Aug 31, 2026 | Marks Peter Ashley | Director | Buy(P) | 48K | $0.50 | $24K |
| Aug 31, 2026 | Stamler David Allen | Chief Executive Officer, Director | Buy(P) | 48K | $0.50 | $24K |
| Jun 15, 2026 | Babarczy Julian Michael | Director | Grant(A) | 2.0M | — | $0 |
| Jun 15, 2026 | Gozlan Lawrence Bernard | Director | Grant(A) | 1.0M | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Alterity Therapeutics Ltd, SEC CIK 0001131343. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ATHE and shows every filing by that issuer.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ATHE